Dose-Related Response to Inhaled Fluticasone Propionate in Patients with Methacholine-Induced Bronchial Hyperresponsiveness: A Double-Blind, Placebo-Controlled Study

1998 ◽  
Vol 35 (2) ◽  
pp. 153-164 ◽  
Author(s):  
Michael J. Noonan ◽  
Paul Chervinsky ◽  
James Wolfe ◽  
Roger Liddle ◽  
Donald J. Kellerman ◽  
...  
Keyword(s):  
Fluticasone Propionate ◽  
Bronchial Hyperresponsiveness ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Related Response

Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: a randomised, double-blind, placebo-controlled study

2014 ◽  
Vol 128 (3) ◽  
pp. 242-248 ◽  
Author(s):  
B-S Goh ◽  
M I M Ismail ◽  
S Husain
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Placebo Group ◽  
Fluticasone Propionate ◽  
Nasal Spray ◽  
Life Assessment ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

AbstractObjective:This study investigated improvements in quality of life associated with eight weeks of montelukast and/or intranasal steroid treatment for moderate to severe allergic rhinitis.Methods:A single-centre, prospective, randomised, double-blind, placebo-controlled study was carried out. Assessments were made using the Rhinoconjunctivitis Quality of Life Questionnaire and symptom scales.Results:A total of 128 patients (aged 13–51 years) were randomly assigned to one of two groups. In the montelukast group, patients were treated with montelukast tablets and fluticasone propionate nasal spray (n = 64). In the placebo group, treatment comprised a placebo and fluticasone propionate. The results showed significant improvements in symptom scores and quality of life scores for both groups after one month and two months of treatment, compared with baseline values; these improvements were significantly greater for the montelukast group compared with the placebo group. The mean number of loratadine tablets taken by each patient during the study period was only 0.73 for the montelukast group compared with 9 for the placebo group.Conclusion:The combination of montelukast tablets and fluticasone propionate nasal spray improved symptom control and overall quality of life for moderate to severe allergic rhinitis patients.

884: Phase I, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Investigate the Safety, Tolerability, and Pharmacokinetics of DA-8159

2004 ◽  
Vol 171 (4S) ◽  
pp. 234-234 ◽  
Author(s):  
Harin Padma-Nathan ◽  
Jae Seung Pacik ◽  
Byoung Ok Ahn ◽  
Kyung Koo Kang ◽  
Mi Young Bahng ◽  
...  
Keyword(s):  
Phase I ◽  
Controlled Study ◽  
Healthy Male ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Male Subjects
Sign in / Sign up

Export Citation Format

Share Document